Immunotherapy drug combination stimulates immune system against resistant cancers 22 Aug 2022 A combination treatment of immunotherapy with the experimental drug guadecitabine may reverse a cancer’s resistance to immunotherapy – making it sensitive to treatment again, a new study has found. Find out more Show/Hide
ICR welcomes MHRA approval of 'search and destroy' prostate cancer treatment 11 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. Find out more Show/Hide
ICR welcomes FDA approval of ‘search and destroy’ treatment 25 Mar 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers. Find out more Show/Hide
New drug combination attacks prostate cancer on two fronts to keep men healthy for longer 08 Jul 2021